Utilizing data from patient-derived xenograft mouse models of human tumors to inform clinical decision making in Molecular Tumor Boards (MTB) deliberations.

e14660 Background: Molecular Tumor Boards (MTB) are often the critical decision-making step in identifying genome-guided treatments for patients with difficult-to-treat cancers, e.g. BRAF mutated metastatic colon cancers. A common challenge for MTBs is prioritizing between two or more actionable variants in a tumor. A potential solution to this challenge is to incorporate drug response in Patient-derived xenografts (PDX) models into MTB...